Bortezomib continues to demonstrate superiority over high-dose dexamethasone in patients with relapsed multiple myeloma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1621, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-dose tamoxifen is not a feasible option in patients with relapsed or refractory multiple myeloma

Inpharma, Vol. 1, Iss. 1439, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Bortezomib beats standard therapy in relapsed multiple myeloma

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

By Chen RA Tu Y Cao Y Liu L Liang Y

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1975-1984

Field House Publishing

Access to resources Recommend Favorite

High-dose chemotherapy + stem cells for multiple myeloma

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P. McKeage Kate

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite